Search
Benzthiazide
go.drugbank.com/drugs/DB00562ApprovedThey inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. … Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalHowever, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect. … Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease.
Synonyms: 1,5-(butylimino)-1,5-dideoxy, D-glucitol, N-(n-Butyl)deoxynojirimycinResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalResmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. … [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD.
Raloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigationalHowever, it has a negligible effect on altering the development and progression of breast cancer itself. … In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigational[L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion. … Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy.
ReN001
go.drugbank.com/drugs/DB05236InvestigationalReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans
Diethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalA appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. … It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
International brands: LineaDroloxifene
go.drugbank.com/drugs/DB15641ExperimentalIts higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.
Categories: Compounds used in a research, industrial, or household settingEvinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalEvinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH. … The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.
Manitimus
go.drugbank.com/drugs/DB06481InvestigationalFK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.
Synonyms: (2Z)-2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)HEPT-2-EN-6-YNAMIDE, (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide